1-855-378-42281-855-378-4228
One of the outpatient treatment options for clients in Campbellsburg who are struggling with opioid dependence and addiction is called opioid maintenance therapy. Some facilities and doctors are authorized to administer certain medications to opioid addicted individuals, many that are opioid-based themselves and are addictive. In low doses the individual doesn't experience being high but also doesn't experience intense cravings and isn't in opioid withdrawal. Methadone is the first drug tried for this reason, but there are alternative choices currently to choose from.
Methadone is an opiate and can be taken at an out-patient clinic licensed to administer the drug, which is taken daily as a pill or liquid. The price of the drug is around $150 a month. Buprenorphine is also an opiate based drug, and is a pill often taken every other day. But different from Methadone that can only be administered in highly structured medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The price monthly of buprenorphine is about three hundred dollars per month for the generic of the medication. There is also a type of buprenorphine that contains the ingredient naloxone, which is a drug that reverses the effects of opioids. Someone taking this version of the drug, also known as Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It too is taken every day, and is priced about $450 a month. Naltrexone is an additional med taken in opioid maintenance therapy, but unlike the other drugs mentioned here it is an opioid blocker and is not an opiate. A person has the choice to take this medication as a monthly shot, and that is called Vivitrol. As an opioid blocker, the drug prevents an individual from experience being high from opioids, and therefore lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 per month.
For All Drug and Alcohol Rehab Centers In Campbellsburg, Click Here.
